pharma news

News

EU clears AZ's SERD camizestrant, as FDA review drags on

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

As patents expire, fampridine is cleared for NHS use in MS

Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.

News

Takeda gets first OK for orexin narcolepsy drug, in China

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

News

Kaken details the data behind its PI3K inhibitor filing

Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.

EU clears AZ's SERD camizestrant, as FDA review drags on

Nuvalent buy delivers new cancer approval for GSK

As patents expire, fampridine is cleared for NHS use in MS

Takeda gets first OK for orexin narcolepsy drug, in China

Repligen builds in cell therapy with $1.5bn BioLife takeover

Kaken details the data behind its PI3K inhibitor filing

Roche's IgAN hopeful sefaxersen passes phase 3 test

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks